A personalised vaccine against melanoma can more than double the survival
rate for patients with the advanced form of this skin cancer. Doctors at
Jefferson Medical College in Philadelphia create customised vaccines from
patients’ own cancer cells by inactivating them and altering their surface
proteins with dinitrophenol. Five-year survival rates in 214 patients with
advanced disease increased from around 20 per cent to 50 per cent and a
randomised phase III trial of 400 patients across the US is planned.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Environment
Can cloud seeding save us from water bankruptcy?
Features
Environment
Carbon credits are flawed, but they can still help save forests
Analysis
ÎçÒ¹¸£Àû1000¼¯ºÏ
PCOS has been officially renamed PMOS, and it’s a momentous move
Comment
Physics
Why do particle physicists like spending time in fields?
Comment
Popular articles
Trending New Scientist articles
1
PCOS has been officially renamed PMOS, and it’s a momentous move
2
Where did the laws of physics come from? I think I've found the answer
3
A new tectonic plate boundary could be forming in southern Africa
4
There has been a sudden increase in the rate of sea level rise
5
Polycystic ovary syndrome may be passed on via chemical tags on DNA
6
Huge study of ancient British DNA reveals only minor Roman influence
7
A lost ancient script reveals how writing as we know it really began
8
What if the idea of the autism spectrum is completely wrong?
9
An unorthodox version of quantum theory could reveal what reality is
10
Slow breathing can calm the mind without any need for mindfulness
